The androgen receptor and mechanisms for androgen independence in prostate cancer

Cancer Investigation

Volumn 23, Issue 6, 2005, Pages 520-528

  Javidan, Javid ^a   Deitch, Arline D ^a   Shi, Xu Bao ^a   De Vere White, Ralph W ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Androgen independence; Androgen receptor; Co activators

Indexed keywords

ANDROGEN; ANDROGEN RECEPTOR; CYTOKINE; DNA; EPIDERMAL GROWTH FACTOR RECEPTOR 2; INTERLEUKIN 6; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE;

CANCER GROWTH; DNA BINDING; GENE AMPLIFICATION; GENE MUTATION; GENETIC TRANSCRIPTION; HUMAN; LIGAND BINDING; MALE; MALIGNANT TRANSFORMATION; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN PHOSPHORYLATION; REVIEW;

ANDROGENS; ANIMALS; HUMANS; MALE; NEOPLASMS, HORMONE-DEPENDENT; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN;

EID: 26844443339     PISSN: 07357907     EISSN: 15324192     Source Type: Journal    
DOI: 10.1080/07357900500202721     Document Type: Review

References (82)

1. Grayhack, J.T.; Keeler, T.C.; Kozlowski, J.M. Carcinoma of the prostate. Hormonal therapy. Cancer 1987, 60 (Suppl. 3), 589-601.
2. Kokontis, J.M.; Liao, S. Molecular action of androgen in the normal and neoplastic prostate. Vitam. Horm. 1999, 55, 219-307.
3. Prins, G.S. Molecular biology of the androgen receptor. Mayo Clin. Proc. 2000 (Suppl. 75), S32-S35.
4. Lubahn, D.B.; et al. Cloning of human androgen receptor complementary DNA and localization to the X chromosome. Science 1988, 240 (4850), 327-330.
5. Geller, J.; Sionit, L. Castration-like effects on the human prostate of a 5 alpha-reductase inhibitor, finasteride. J. Cell. Biochem., Suppl. 1992, 16H, 109-112.
6. Pollard, M.; Luckert, P.H.; Sporn, M.B. Prevention of primary prostate cancer in Lobund-Wistar rats by N-(4-hydroxyphenyl)retinamide. Cancer Res. 1991, 51 (13), 3610-3611.
7. Arnold, J.T.; Isaacs, J.T. Mechanisms involved in the progression of androgen-independent prostate cancers: it is not only the cancer cell's fault. Endocr.-Relat. Cancer 2002, 9 (1), 61-73.
8. Isaacs, J.T. The biology of hormone refractory prostate cancer. Why does it develop? Urol. Clin. North Am. 1999, 26 (2), 263-273.
9. De La Taille, A.; et al. Hormone-refractory prostate cancer: a multi-step and multi-event process. Prostate Cancer Prostatic Dis. 2001, 4 (4), 204-212.
10. Gelmann, E.P. Molecular biology of the androgen receptor. J. Clin. Oncol. 2002, 20 (13), 3001-3015.
11. Sartor, O.; Zheng, Q.; Eastham, J.A. Androgen receptor gene CAG repeat length varies in a race-specific fashion in men without prostate cancer. Urology 1999, 53 (2), 378-380.
12. Giovannucci, E.; et al. The CAG repeat within the androgen receptor gene and its relationship to prostate cancer. Proc. Natl. Acad. Sci. U. S. A. 1997, 94 (7), 3320-3323.
13. Hardy, D.O.; et al. Androgen receptor CAG repeat lengths in prostate cancer: correlation with age of onset. J. Clin. Endocrinol. Metab. 1996, 81 (12), 4400-4405.
14. Bratt, O.; et al. CAG repeat length in the androgen receptor gene is related to age at diagnosis of prostate cancer and response to endocrine therapy, but not to prostate cancer risk. Br. J. Cancer 1999, 81 (4), 672-676.
15. Nam, R.K.; et al. Significance of the CAG repeat polymorphism of the androgen receptor gene in prostate cancer progression. J. Urol. 2000, 164 (2), 567-572.
16. Schwabe, J.W.; et al. The crystal structure of the estrogen receptor DNA-binding domain bound to DNA: how receptors discriminate between their response elements. Cell 1993, 75 (3), 567-578.
17. Nelson, C.C.; et al. Determinants of DNA sequence specificity of the androgen, progesterone, and glucocorticoid receptors: evidence for differential steroid receptor response elements. Mol. Endocrinol. 1999, 13 (12), 2090-2107.
18. Alen, P.; et al. The androgen receptor amino-terminal domain plays a key role in p160 coactivator-stimulated gene transcription. Mol. Cell. Biol. 1999, 19 (9), 6085-6097.
19. Glass, C.K.; Rose, D.W.; Rosenfeld, M.G. Nuclear receptor coactivators. Curr. Opin. Cell Biol. 1997, 9 (2), 222-232.
20. Zhang, X.; et al. A nuclear receptor corepressor modulates transcriptional activity of antagonist-occupied steroid hormone receptor. Mol. Endocrinol. 1998, 12 (4), 513-524.
21. Linja, M.J.; et al. Amplification and overexpression of androgen receptor gene in hormone-refractory prostate cancer. Cancer Res. 2001, 61 (9), 3550-3555.
22. Latil, A.; et al. Evaluation of androgen, estrogen (ER alpha and ER beta), and progesterone receptor expression in human prostate cancer by real-time quantitative reverse transcription-polymerase chain reaction assays. Cancer Res. 2001, 61 (5), 1919-1926.
23. Ruizeveld de Winter, J.A.; et al. Androgen receptor status in localized and locally progressive hormone refractory human prostate cancer. Am. J. Pathol. 1994, 144 (4), 735-746.
24. Balk, S.P. Androgen receptor as a target in androgen-independent prostate cancer. Urology 2002, 60 (3 Suppl. 1), 132-138 discussion 138-9.
25. de Vere White, R.; et al. Human androgen receptor expression in prostate cancer following androgen ablation. Eur. Urol. 1997, 31 (1), 1-6.
26. Majumder, P.K.; Wadhwa, S.N.; Kumar, V.L. Androgen receptor transcript level in benign hypertrophy and carcinoma of the human prostate. Urol. Int. 1997, 59 (4), 231-235.
27. Koivisto, P.; et al. Androgen receptor gene amplification: a possible molecular mechanism for androgen deprivation therapy failure in prostate cancer. Cancer Res. 1997, 57 (2), 314-319.
28. Visakorpi, T.; et al. In vivo amplification of the androgen receptor gene and progression of human prostate cancer. Nat. Genet. 1995, 9 (4), 401-406.
29. Edwards, J.; et al. Androgen receptor gene amplification and protein expression in hormone refractory prostate cancer. Br. J. Cancer 2003, 89 (3), 552-556.
30. Palmberg, C.; et al. Androgen receptor gene amplification at primary progression predicts response to combined androgen blockade as second line therapy for advanced prostate cancer. J. Urol. 2000, 164 (6), 1992-1995.
31. Wilding, G.; Chen, M.; Gelmann, E.P. Aberrant response in vitro of hormone-responsive prostate cancer cells to antiandrogens. Prostate 1989, 14 (2), 103-115.
32. Newmark, J.R.; Hardy, D.O.; Tonb, D.C.; Carter, B.S.; Epstein, J.I.; Issacs, W.B.; Brown, T.R.; Barrack, E.R. Androgen receptor mutations in human prostate cancer. Proc. Natl. Acad. Sci. U. S. A. 1992, 89, 6319-6323.
33. Suzuki, H.; et al. Codon 877 mutation in the androgen receptor gene in advanced prostate cancer: relation to antiandrogen withdrawal syndrome. Prostate 1996, 29 (3), 153-158.
34. Marcelli, M.; et al. Androgen receptor mutations in prostate cancer. Cancer Res. 2000, 60 (4), 944-949.
35. Taplin, M.E.; et al. Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer. N. Engl. J. Med. 1995, 332 (21), 1393-1398.
36. Tilley, W.D.; et al. Mutations in the androgen receptor gene are associated with progression of human prostate cancer to androgen independence. Clin. Cancer Res. 1996, 2 (2), 277-285.
37. Taplin, M.E.; et al. Selection for androgen receptor mutations in prostate cancers treated with androgen antagonist. Cancer Res. 1999, 59 (11), 2511-2515.
38. Hyytinen, E.R.; et al. Pattern of somatic androgen receptor gene mutations in patients with hormone-refractory prostate cancer. Lab. Invest. 2002, 82 (11), 1591-1598.
39. Taplin, M.E.; Balk, S.P. Androgen receptor: a key molecule in the progression of prostate cancer to hormone independence. J. Cell. Biochem. 2004, 91 (3), 483-490.
40. Shi, X.B.; et al. Functional analysis of 44 mutant androgen receptors from human prostate cancer. Cancer Res. 2002, 62 (5), 1496-1502.
41. Onate, S.A.; et al. Sequence and characterization of a coactivator for the steroid hormone receptor superfamily. Science 1995, 270 (5240), 1354-1357.
42. Shibata, H.; et al. Role of co-activators and co-repressors in the mechanism of steroid/thyroid receptor action. Recent Prog. Horm. Res. 1997, 52, 141-164 discussion 164-5.
43. Webb, P.; et al. Estrogen receptor activation function 1 works by binding p160 coactivator proteins. Mol. Endocrinol. 1998, 12 (10), 1605-1618.
44. Rowan, B.G.; et al. 8-Bromo-cyclic AMP induces phosphorylation of two sites in SRC-1 that facilitate ligand-independent activation of the chicken progesterone receptor and are critical for functional cooperation between SRC-1 and CREB binding protein. Mol. Cell. Biol. 2000, 20 (23), 8720-8730.
45. Suzuki, H.; et al. Androgen receptor involvement in the progression of prostate cancer. Endocr.-Relat. Cancer 2003, 10 (2), 209-216.
46. Gregory, C.W.; et al. A mechanism for androgen receptor-mediated prostate cancer recurrence after androgen deprivation therapy. Cancer Res. 2001, 61 (11), 4315-4319.
47. Heinlein, C.A.; Chang, C. Androgen receptor (AR) coregulators: an overview. Endocr. Rev. 2002, 23 (2), 175-200.
48. Horwitz, K.B.; et al. Nuclear receptor coactivators and corepressors. Mol. Endocrinol. 1996, 10 (10), 1167-1177.
49. Aarnisalo, P.; Palvimo, J.J.; Janne, O.A. CREB-binding protein in androgen receptor-mediated signaling. Proc. Natl. Acad. Sci. U. S. A. 1998, 95 (5), 2122-2127.
50. Halkidou, K.; et al. Expression of Tip60, an androgen receptor coactivator, and its role in prostate cancer development. Oncogene 2003, 22 (16), 2466-2477.
51. Dong, J.T.; Isaacs, W.B.; Isaacs, J.T. Molecular advances in prostate cancer. Curr. Opin. Oncol. 1997, 9 (1), 101-107.
52. Harris, C.C.; Hollstein, M. Clinical implications of the p53 tumor-suppressor gene. N. Engl. J. Med. 1993, 329 (18), 1318-1327.
53. Koivisto, P.A.; Rantala, I. Amplification of the androgen receptor gene is associated with P53 mutation in hormone-refractory recurrent prostate cancer. J. Pathol. 1999, 187 (2), 237-241.
54. Nesslinger, N.J.; Shi, X.B.; deVere White, R.W. Androgen-independent growth of LNCaP prostate cancer cells is mediated by gain-of-function mutant p53. Cancer Res. 2003, 63 (9), 2228-2233.
55. McDonnell, T.J.; et al. Expression of bcl-2 oncoprotein and p53 protein accumulation in bone marrow metastases of androgen independent prostate cancer. J. Urol. 1997, 157 (2), 569-574.
56. Bubendorf, L.; et al. Survey of gene amplifications during prostate cancer progression by high-throughout fluorescence in situ hybridization on tissue microarrays. Cancer Res. 1999, 59 (4), 803-806.
57. Hansson, J.; Abrahamsson, P.A. Neuroendocrine pathogenesis in adenocarcinoma of the prostate. Ann. Oncol. 2001, 12 (Suppl. 2), S145-S152.
58. Ferrero-Pous, M.; et al. Serum chromogranin-A in advanced prostate cancer. BJU Int. 2001, 88 (7), 790-796.
59. Debes, J.D.; Tindall, D.J. The role of androgens and the androgen receptor in prostate cancer. Cancer Lett. 2002, 187 (1-2), 1-7.
60. Culig, Z.; et al. Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-I, keratinocyte growth factor, and epidermal growth factor. Cancer Res. 1994, 54 (20), 5474-5478.
61. Chan, J.M.; et al. Plasma insulin-like growth factor-1 and prostate cancer risk: a prospective study. Science 1998, 279 (5350), 563-566.
62. Sadar, M.D.; Gleave, M.E. Ligand-independent activation of the androgen receptor by the differentiation agent butyrate in human prostate cancer cells. Cancer Res. 2000, 60 (20), 5825-5831.
63. Yamamoto, A.; et al. Cyclin E as a coactivator of the androgen receptor. J. Cell Biol. 2000, 150 (4), 873-880.
64. Nazareth, L.V.; Weigel, N.L. Activation of the human androgen receptor through a protein kinase A signaling pathway. J. Biol. Chem. 1996, 271 (33), 19900-19907.
65. Hobisch, A.; et al. Interleukin-6 regulates prostate-specific protein expression in prostate carcinoma cells by activation of the androgen receptor. Cancer Res. 1998, 58 (20), 4640-4645.
66. Drachenberg, D.E.; et al. Circulating levels of interleukin-6 in patients with hormone refractory prostate cancer. Prostate 1999, 41 (2), 127-133.
67. Nakashima, J.; et al. Serum interleukin 6 as a prognostic factor in patients with prostate cancer. Clin. Cancer Res. 2000, 6 (7), 2702-2706.
68. Ueda, T.; Bruchovsky, N.; Sadar, M.D. Activation of the androgen receptor N-terminal domain by interleukin-6 via MAPK and STAT3 signal transduction pathways. J. Biol. Chem. 2002, 277 (9), 7076-7085.
69. Lin, D.L.; et al. Interleukin-6 induces androgen responsiveness in prostate cancer cells through up-regulation of androgen receptor expression. Clin. Cancer Res. 2001, 7 (6), 1773-1781.
70. Craft, N.; et al. A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase. Nat. Med. 1999, 5 (3), 280-285.
71. Wen, Y.; et al. HER-2/neu promotes androgen-independent survival and growth of prostate cancer cells through the Akt pathway. Cancer Res. 2000, 60 (24), 6841-6845.
72. Yeh, S.; et al. From HER2/neu signal cascade to androgen receptor and its coactivators: a novel pathway by induction of androgen target genes through MAP kinase in prostate cancer cells. Proc. Natl. Acad. Sci. U. S. A. 1999, 96 (10), 5458-5463.
73. Lee, M.S.; et al. ErbB-2 signaling is involved in regulating PSA secretion in androgen-independent human prostate cancer LNCaP C-81 cells. Oncogene 2003, 22 (5), 781-796.
74. Morris, M.J.; et al. HER-2 profiling and targeting in prostate carcinoma. Cancer 2002, 94 (4), 980-986.
75. Sadar, M.D.; Hussain, M.; Bruchovsky, N. Prostate cancer: molecular biology of early progression to androgen independence. Endocr.-Relat. Cancer 1999, 6 (4), 487-502.
76. Abreu-Martin, M.T.; et al. Mitogen-activated protein kinase kinase kinase 1 activates androgen receptor-dependent transcription and apoptosis in prostate cancer. Mol. Cell. Biol. 1999, 19 (7), 5143-5154.
77. Tan, J.; et al. Dehydroepiandrosterone activates mutant androgen receptors expressed in the androgen-dependent human prostate cancer xenograft CWR22 and LNCaP cells. Mol. Endocrinol. 1997, 11 (4), 450-459.
78. Gregory, C.W.; et al. Androgen receptor stabilization in recurrent prostate cancer is associated with hypersensitivity to low androgen. Cancer Res. 2001, 61 (7), 2892-2898.
79. Culig, Z.; et al. Switch from antagonist to agonist of the androgen receptor bicalutamide is associated with prostate tumour progression in a new model system. Br. J. Cancer 1999, 81 (2), 242-251.
80. Navarro, D.; et al. Transition to androgen-independence in prostate cancer. J. Steroid Biochem. Mol. Biol. 2002, 81 (3), 191-201.
81. Gregory, C.W.; et al. Androgen receptor expression in androgen-independent prostate cancer is associated with increased expression of androgen-regulated genes. Cancer Res. 1998, 58 (24), 5718-5724.
82. Jenster, G. Ligand-independent activation of the androgen receptor in prostate cancer by growth factors and cytokines. J. Pathol. 2000, 191 (3), 227-228.